基于校正CBCT的乳腺癌患者每日剂量评估:剂量与并发症风险评估的准确性
本研究纳入76例接受部分VMAT光子技术治疗的乳腺癌患者,所有患者CBCT与计划CT相比乳房有至少5 mm变化。采用四种CBCT校正方法,以重复CT为参考评估图像质量和剂量准确性。结果显示解析校正转换、深度学习校正和虚拟校正可用于光子放疗疗程中的准确剂量评估。
要点
- 除CBCTHU外,所有校正CBCT的CBCT-ROI的MAE均低于66 HU。
- CBCTCC、CTDL和CTv在CTV区域未见显著剂量差异。
- 仅CBCTHU偏差显著(p < 0.01),平均剂量偏差1.7%(± 1.1%)。
核心结论
- 解析校正转换、深度学习校正和虚拟校正方法可用于准确的CBCT校正,并可用于乳腺癌患者光子放疗疗程中的剂量评估。
研究设计与样本
- 纳入76例接受部分VMAT光子技术(70%适形、30% VMAT)治疗的乳腺癌患者。
- 所有患者CBCT与计划CT相比乳房有至少5 mm变化(肿胀或缩小),并在该CBCT 3天内采集了用于剂量评估的重复CT。
- 原始CBCT采用四种方法校正:HU覆盖校正(CBCTHU)、解析校正与转换(CBCTCC)、深度学习校正(CTDL)和虚拟校正(CTv)。
- 图像质量评估为计算全乳临床靶区(CTV)和CBCT视野减去2 cm区域(CBCT-ROI)相对于重复CT的平均绝对误差(MAE)和平均误差(ME)。
- 使用临床治疗计划在所有图像集上计算剂量并进行伽马通过率分析。
主要发现
- 除CBCTHU的MAE为142 HU外,所有校正CBCT的CBCT-ROI的MAE均低于66 HU。
- CBCTCC、CTDL和CTv在CTV区域未见显著剂量差异。
- 仅CBCTHU偏差显著(p < 0.01),导致平均剂量偏差1.7%(± 1.1%)。
- 所有校正CBCT在2%/2 mm下的伽马通过率均> 95%。
关键数值与推荐
- CBCTHU的CBCT-ROI的MAE为142 HU,其余校正CBCT的CBCT-ROI的MAE均低于66 HU。
- CBCTHU偏差显著(p < 0.01),平均剂量偏差1.7%(± 1.1%)。
- 所有校正CBCT在2%/2 mm下的伽马通过率均> 95%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The goal of this study is to validate different CBCT correction methods to select the superior method that can be used for dose evaluation in breast cancer patients with large anatomical changes treated with photon irradiation. MATERIALS AND METHOD: Seventy-six breast cancer patients treated with a partial VMAT photon technique (70% conformal, 30% VMAT) were included in this study. All patients showed at least a 5 mm variation (swelling or shrinkage) of the breast on the CBCT compared to the planning-CT (pCT) and had a repeat-CT (rCT) for dose evaluation acquired within 3 days of this CBCT. The original CBCT was corrected using four methods: (1) HU-override correction (CBCTHU), (2) analytical correction and conversion (CBCTCC), (3) deep learning (DL) correction (CTDL) and (4) virtual correction (CTV). Image quality evaluation consisted of calculating the mean absolute error (MAE) and mean error (ME) within the whole breast clinical target volume (CTV) and the field of view of the CBCT minus 2 cm (CBCT-ROI) with respect to the rCT. The dose was calculated on all image sets using the clinical treatment plan for dose and gamma passing rate analysis. RESULTS: The MAE of the CBCT-ROI was below 66 HU for all corrected CBCTs, except for the CBCTHU with a MAE of 142 HU. No significant dose differences were observed in the CTV regions in the CBCTCC, CTDL and CTv. Only the CBCTHU deviated significantly (p < 0.01) resulting in 1.7% (± 1.1%) average dose deviation. Gamma passing rates were > 95% for 2%/2 mm for all corrected CBCTs. CONCLUSION: The analytical correction and conversion, deep learning correction and virtual correction methods can be applied for an accurate CBCT correction that can be used for dose evaluation during the course of photon radiotherapy of breast cancer patients.
引用
- Hamming VC, Andersson S, Maduro JH, et al. Daily dose evaluation based on corrected CBCTs for breast cancer patients: accuracy of dose and complication risk assessment. Radiat Oncol. 2022. PMID: 36510254. doi:10.1186/s13014-022-02174-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。